Burden of illness and research investments in translational sciences for pharmaceuticals in metastatic cancers. - PubMed - NCBI

Burden of illness and research investments in translational sciences for pharmaceuticals in metastatic cancers. - PubMed - NCBI

J Comp Eff Res. 2017 Jan;6(1):15-24. doi: 10.2217/cer-2016-0021. Epub 2016 Dec 9.

Burden of illness and research investments in translational sciences for pharmaceuticals in metastatic cancers.

Wang WJ1, Robertson JC2, Basu A1,2.

Author information

Abstract

AIM:

To explore whether investments in translational sciences for six metastatic cancers follow idiosyncratic returns to those investments rather than levels of burden of illness (BI).

METHODS:

Associate the number of translational clinical trials in the USA involving oncolytic drugs approved during 2008-2013 and the level (in 2008) and changes (2002-2008 and 2008-2014) in cancer-specific years of life lost.

RESULTS:

Investments in trials were positively associated only with contemporary changes in BI (2008-2014). The relationship was stronger for government-sponsored comparative-effectiveness trials than for industry.

CONCLUSION:

Translational research investments follow anticipated changes to BI levels. Systematic quantification of these expected returns from specific investments can help guide investment decisions in translational health sciences and generate productive dialogue across stakeholders.

KEYWORDS:

burden-of-illness; comparative effectiveness research; metastatic cancer; pharmaceuticals; translational research investments

PMID:

 

27934549

 

PMCID:

 

PMC5220454

 [Available on 2018-01-01]

 

DOI:

 

10.2217/cer-2016-0021